Literature DB >> 29665733

Natural History, Predictors of Outcome, and Effects of Treatment in Thoracic Spinal Cord Injury: A Multi-Center Cohort Study from the North American Clinical Trials Network.

Jefferson R Wilson1, Blessing N R Jaja1,2, Brian K Kwon3, James D Guest4, James S Harrop5, Bizhan Aarabi6, Christopher I Shaffrey7, Jetan H Badhiwala2, Elizabeth G Toups8, Robert G Grossman8, Michael G Fehlings2.   

Abstract

The course, treatment response, and recovery potential after acute traumatic spinal cord injury (SCI) have been shown to differ depending on the neurological level of injury. There are limited data focused on thoracic-level injuries, however. A cohort of 86 patients from the prospectively maintained North American Clinical Trials Network SCI registry were identified and studied to characterize the patterns of neurological recovery and to determine rates of acute hospital death and pulmonary complications. Regression analyses were used to examine the relationship between timing of surgery and administration of methylprednisolone on neurologic and clinical outcomes. Neurological conversion (≥1 American Spinal Injury Association Impairment Scale [AIS] grade improvement) was poorest for AIS grade A patients; 14.3% converted at last available follow-up (mean eight months). While rates of conversion were more optimistic for AIS-B patients (54.5%) and AIS C injuries (77.8%) at the same time point, none of the AIS grade D patients converted to AIS E. At last available follow-up (mean eight months), the magnitudes of lower motor extremity score (LEMS) change were highest for AIS C injuries (21.9 points), then AIS B (17.7 points), AIS D (16.4 points), and finally AIS A (2.5 points) (p < 0.05). Early surgical intervention (<24 h post-injury) was independently associated with an additional seven points in motor recovery and a 60% decreased incidence of pulmonary events (p < 0.05). Methylprednisolone administration was not an independent predictor of neurological outcome or pulmonary complications. Evaluation of this cohort obtained from a modern multi-center SCI registry provides an update on the natural history, acute death, and incidence of pulmonary complications after traumatic thoracic SCI. Although small sample size limited the extent of analyses possible, early surgical treatment was associated with significantly larger motor recovery and lower rates of pulmonary complications.

Entities:  

Keywords:  North American Clinical Trials Network; complications; methylprednisolone; neurological recovery; thoracic; timing of surgery; traumatic spinal cord injury

Mesh:

Year:  2018        PMID: 29665733     DOI: 10.1089/neu.2017.5535

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  11 in total

1.  International surveillance study in acute spinal cord injury confirms viability of multinational clinical trials.

Authors:  Armin Curt; Catherine R Jutzeler; Lucie Bourguignon; Bobo Tong; Fred Geisler; Martin Schubert; Frank Röhrich; Marion Saur; Norbert Weidner; Rüdiger Rupp; Yorck-Bernhard B Kalke; Rainer Abel; Doris Maier; Lukas Grassner; Harvinder S Chhabra; Thomas Liebscher; Jacquelyn J Cragg; John Kramer
Journal:  BMC Med       Date:  2022-06-14       Impact factor: 11.150

2.  Exoskeleton-assisted walking improves pulmonary function and walking parameters among individuals with spinal cord injury: a randomized controlled pilot study.

Authors:  Xiao-Na Xiang; Hui-Yan Zong; Yi Ou; Xi Yu; Hong Cheng; Chun-Ping Du; Hong-Chen He
Journal:  J Neuroeng Rehabil       Date:  2021-05-24       Impact factor: 4.262

3.  Acute hyperextension myelopathy in children: Radiographic predictors of clinical improvement.

Authors:  Yulong Wang; Lian Zeng; Fengzhao Zhu; Guixiong Huang; Yizhou Wan; Sheng Yao; Kaifang Chen; Xiaodong Guo
Journal:  Spinal Cord       Date:  2022-01-20       Impact factor: 2.473

4.  Early Surgery for Traumatic Spinal Cord Injury: Where Are We Now?

Authors:  Jefferson R Wilson; Christopher D Witiw; Jetan Badhiwala; Brian K Kwon; Michael G Fehlings; James S Harrop
Journal:  Global Spine J       Date:  2020-01-06

5.  Acute Implantation of a Bioresorbable Polymer Scaffold in Patients With Complete Thoracic Spinal Cord Injury: 24-Month Follow-up From the INSPIRE Study.

Authors:  Kee D Kim; K Stuart Lee; Domagoj Coric; James S Harrop; Nicholas Theodore; Richard M Toselli
Journal:  Neurosurgery       Date:  2022-04-22       Impact factor: 5.315

6.  Variability in time to surgery for patients with acute thoracolumbar spinal cord injuries.

Authors:  Jetan H Badhiwala; Gerald Lebovic; Michael Balas; Leodante da Costa; Avery B Nathens; Michael G Fehlings; Jefferson R Wilson; Christopher D Witiw
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

7.  A Randomized Controlled Trial of Early versus Late Surgical Decompression for Thoracic and Thoracolumbar Spinal Cord Injury in 73 Patients.

Authors:  Ali Haghnegahdar; Reza Behjat; Soheil Saadat; Jetan Badhiwala; Majid Reza Farrokhi; Amin Niakan; Keyvan Eghbal; Ehsan Barzideh; Abtin Shahlaee; Fariborz Ghaffarpasand; Zahra Ghodsi; Alexander R Vaccaro; Mohsen Sadeghi-Naini; Michael G Fehlings; James David Guest; Pegah Derakhshan; Vafa Rahimi-Movaghar
Journal:  Neurotrauma Rep       Date:  2020-09-18

8.  Prediction of independence in bowel function after spinal cord injury: validation of a logistic regression model.

Authors:  Omar Khan; Jetan H Badhiwala; Michael G Fehlings
Journal:  Spinal Cord       Date:  2020-09-22       Impact factor: 2.772

9.  Pursuing More Aggressive Timelines in the Surgical Treatment of Traumatic Spinal Cord Injury (TSCI): A Retrospective Cohort Study with Subgroup Analysis.

Authors:  Tobias Bock; Raban Arved Heller; Patrick Haubruck; Tim Friedrich Raven; Maximilian Pilz; Arash Moghaddam; Bahram Biglari
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

10.  Tissue bridges predict recovery after traumatic and ischemic thoracic spinal cord injury.

Authors:  Dario Pfyffer; Eveline Huber; Reto Sutter; Armin Curt; Patrick Freund
Journal:  Neurology       Date:  2019-09-20       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.